Ardelyx (NASDAQ:ARDX) Receiving Somewhat Favorable News Coverage, Accern Reports

News coverage about Ardelyx (NASDAQ:ARDX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.5212185081663 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Shares of ARDX stock traded down $0.05 during trading on Wednesday, hitting $5.50. 160,290 shares of the company’s stock were exchanged, compared to its average volume of 296,149. The firm has a market capitalization of $254.68, a P/E ratio of -4.04 and a beta of 0.76. Ardelyx has a 1-year low of $4.05 and a 1-year high of $14.15.

Several equities analysts have issued reports on ARDX shares. Zacks Investment Research raised shares of Ardelyx from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Tuesday, January 30th. Citigroup lifted their price target on shares of Ardelyx from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, November 29th. ValuEngine lowered shares of Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Ladenburg Thalmann Financial Services cut their price target on shares of Ardelyx from $19.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 22nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target (down from $13.00) on shares of Ardelyx in a report on Tuesday, November 28th. Three equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $12.93.

TRADEMARK VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/ardelyx-ardx-earning-somewhat-favorable-media-coverage-study-finds/1923773.html.

About Ardelyx

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.